On October 19, 2021 SHINE Technologies LLC, a nuclear technology company, reported that it has received a $35-million award from the U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA) (Press release, Shine Medical Technologies, OCT 19, 2021, View Source [SID1234591518]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The award is part of DOE/NNSA efforts to establish a reliable, U.S.-produced supply of molybdenum-99, or Mo-99, without using highly enriched uranium. Mo-99 is the most commonly used medical isotope, relied on for approximately 40 million patient procedures around the world every year to diagnose conditions such as heart disease and cancer.
"We are really excited to continue and expand our strong partnership with DOE/NNSA," said Greg Piefer, Chairman and CEO of SHINE. "The agency’s support of our Mo-99 project continues to be an accelerant in our efforts to create a large domestic supply of Mo-99, which will both improve the lives of millions of patients and make the world safer through the elimination of highly enriched uranium anywhere in the supply chain."
SHINE-Production-Facility-Construction-10.2021
SHINE plans to use its fusion-based technology to produce medical isotopes at its first-of-a-kind facility in Janesville, Wis.
Construction of SHINE’s medical isotope production facility in Janesville, continues to progress after achieving weathertight status earlier this year. Reaching weathertight status marked the beginning of installation of the plant’s process equipment. Crews most recently began prepping the concrete bays where the neutron generators will be installed. The first two generators are completed and undergoing commissioning. The facility will be the first of its kind and will use SHINE’s patented fusion-based technology to produce Mo-99.
SHINE-Production-Facility-Interior-Construction-10.2021
Progress continues at SHINE’s Moly-99 plant in Janesville, Wis., where equipment is being installed that will produce medical isotopes.
The award was made under a cooperative agreement between DOE/NNSA and SHINE that requires SHINE to provide $35 million to receive the same amount in a matching award from DOE/NNSA.